COMBINED THERAPY FOR MALIGNANT TUMOR TREATMENT Russian patent published in 2020 - IPC A61K39/00 A61P35/00 

Abstract RU 2733315 C2

FIELD: medicine; oncology.

SUBSTANCE: present invention relates to combined therapy of malignant tumors. That is ensured by introducing variant 4D5 chimeric antibody in combination with a molecule which specifically binds a cell surface receptor or a ligand thereof which regulates an immune control point. 4D5 antibody contains a variable light chain domain comprising the amino acid sequence SEQ ID NO: 4, and heavy chain, which contains a variant Fc-site exhibiting increased ADCC activity, wherein the heavy chain contains an amino acid sequence selected from a group consisting of SEQ ID NO: 9, SEQ ID NO: 11 and SEQ ID NO: 13. A molecule which specifically binds a cell surface receptor comprises a variant Fc region having at least one modification relative to the wild-type IgG1 Fc region or the IgG4 Fc region, wherein said variant Fc region of said molecule exhibits reduced ADCC activity with respect to a comparable molecule which contains wild-type IgG1 Fc region.

EFFECT: combined administration of said agents provides effective treatment of tumors expressing HER2/neu, including refractory to trastuzumab therapy.

28 cl, 7 tbl, 8 ex, 15 dwg

Similar patents RU2733315C2

Title Year Author Number
BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE 2019
  • Ellerman, Diego
  • Dzhunttila, Timu, T.
  • Lombana, Tvila, Noell
  • Slaga, Dionisos
  • Spiss, Kristof
RU2800779C2
COMPOSITIONS AND METHODS FOR MODULATING THE TRANSMISSION OF A LAIR SIGNAL 2017
  • Flies, Dallas, Benjamin
  • Liu, Linda
  • Langermann, Solomon
RU2757394C2
SOLUBLE UNIVERSAL REINFORCING ADCC SYNTHETIC FUSED GENE, PEPTIDE TECHNOLOGY AND USE THEREOF 2015
  • Unniraman, Shyam
  • Li, Chiang, J.
RU2725807C2
A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS 2016
  • Fjaellskog, Marie-Louise
  • Cameron, John
  • Cao, Zhu
  • Cipolletta, Daniela
  • Macisaac, Kenzie
RU2742494C2
POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM 2018
  • Chang, Gregory, P.
  • Cheung, Ann, F.
  • Haney, William
  • Grinberg, Asya
RU2809125C2
VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS 2014
  • Gennaro Lynn A.
  • Kao Yung-Hsiang
  • Zhang Yonghua
RU2737727C2
IMMUNOCYTOKINES AND THEIR USE 2021
  • Wu Ellen
  • Wu Xiaoyun
  • Wakefield John
RU2818371C1
BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 2014
  • Weisser Nina E.
  • Ng Gordon Yiu Kon
  • Wickman Grant Raymond
  • Dixit Surjit Bhimarao
  • Escpbar-Cabrera Eric
  • Sanches Mario
RU2737882C2
BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY 2019
  • Her, Jeng-Horng
  • You, Jhong-Jhe
  • Hsu, Ching-Hsuan
  • Huang, Po-Lin
RU2756899C1
VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES 2019
  • Bonvini, Etsio
  • Khuan, Lin
  • Lam, Chia-In Kao
  • Chichili, Gurunad Reddi
  • Alderson, Ralf Froman
  • Mur, Pol A.
  • Dzhonson, Lesli S.
RU2810222C2

RU 2 733 315 C2

Authors

Wiggington Jon Marc

Pandya Naimish Bharat

Lechleider Robert Joseph

Koenig Scott

Bonvini Ezio

Dates

2020-10-01Published

2016-06-09Filed